Portal de investigación
Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- López Muñoz AM
- González Flores E
- Carral Maseda A
- Pimentel Cáceres P
- Afonso Gómez R
- López López C
- Jimeno Maté R
- Reina Zoilo JJ
- Castañón López C
- Salgado Fernández M
- Asensio Martínez E
- Martín Gómez T
Grupos
Abstract
PURPOSE: To describe the dosing patterns of regorafenib in a real-world population of patients with metastatic colorectal cancer (mCRC) in a routine clinical practice setting in Spain, focusing on the starting dose of regorafenib. METHODS: An observational, retrospective, multicenter study that included patients = 18 years old who had histologically documented mCRC and who had initiated treatment with regorafenib since January 2017. Post hoc categorization of dosing patterns revealed the following: initial dose < 160 mg and dose escalation, initial dose < 160 mg and maintenance, initial dose equal to 160 mg and maintenance, and initial dose equal to 160 mg and dose reduction. RESULTS: Most patients (152/241, 63.8%) initiated treatment with regorafenib at doses < 160 mg. There was large variation in the starting dose of regorafenib over time: in 2017, most patients (59%) initiated regorafenib at a dose of 160 mg, this proportion decreased to 6% in 2021. There were no significant differences in the median progression-free survival according to the regorafenib dose patterns during the first two cycles. The proportion of patients who reported at least one adverse event (AE), had a grade 3-4 AE or had an AE leading to dose reduction was greater in the group of patients who received an initial dose equal to 160 and reduction. CONCLUSIONS: Our results indicate that physicians in Spain have gradually adopted a dose-escalation approach during cycle 1, which is a common practice for starting treatment with a reduced dose (< 160 mg/day), a strategy that seems to improve tolerability while maintaining efficacy. TRIAL REGISTRATION: Not applicable.
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 1176-1184
- PubMed:
- 39127984
- Factor de Impacto:
- 0,764 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical & Translational Oncology SPRINGER INT PUBL AG
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- Dosing patterns; Metastatic colorectal cancer; Regorafenib